**Name of Journal: *World Journal of Clinical Cases***

**Manuscript NO: 50926**

**Manuscript Type: ORIGINAL ARTICLE**

***Observational Study***

**Comparison of intra-articular injection of parecoxib *vs* oral administration of celecoxib for the clinical efficacy in the treatment of early knee osteoarthritis**

Lu L *et al*. Efficacy of intra-articular injection of parecoxib

**Lu Lu,** **Yu Xie, Ke Gan, Xiao-Wen Huang**

**Lu Lu, Yu Xie, Ke Gan,** Department of Rheumatology,Affiliated Hospital of Nanjing University of Chinese Medicine (Jiangsu Province Hospital of Chinese Medicine), Nanjing 210029, Jiangsu Province, China

**Xiao-Wen Huang,**Department of Orthopedics,First Affiliated Hospital of Nanjing Medical University (Jiangsu Province Hospital), Nanjing 210029, Jiangsu Province, China

**ORCID number:** Lu Lu (0000-0001-6435-2492); Yu Xie (0000-0002-6570-1858); Ke Gan (0000- 0001-6458-3098); Xiao-Wen Huang (0000-0001-9238-9065).

**Author contributions:** Lu L and Huang XW contributed to study conception and design; Lu L, Xie Y and Gan Kcontributed to data acquisition, data analysis and interpretation, and writing of article; all of authors contributed to editing, reviewing and final approval of article.

**Supported by** National Natural Science Foundation of China, NO. 81774274; and Project of Jiangsu Provincial Hospital of Traditional Chinese Medicine, NO. Y19058.

**Institutional review board statement:** The study was approved by the Ethics Committee ofAffiliated Hospital of Nanjing University of Chinese Medicine.

**Informed consent statement:** All patients gave informed consent.

**Conflict-of-interest statement:** All authors have declared that no conflict of interest exists.

**Data sharing statement:** No additional data are available.

**STROBE statement:** The authors have read the STROBE Statement, and the manuscript was prepared and revised according to the STROBE Statement.

**Open-access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

**Manuscript source:** Unsolicited manuscript

**Corresponding author: Xiao-Wen Huang, MD, Professor,** Department of Orthopedics,First Affiliated Hospital of Nanjing Medical University (Jiangsu Province Hospital), No. 300 Guangzhou Road, Nanjing 210029, Jiangsu Province, China. [jiangsuaaa@aliyun.com](mailto:jiangsuaaa@aliyun.com)

**Telephone:** +86-25-86624213

**Fax:** +86-25-86624213

**Received:** September 30, 2019

**Peer-review started:** September 30, 2019

**First decision:** October 23, 2019

**Revised:** November 5, 2019

**Accepted:** November 15, 2019

**Article in press:** November 15, 2019

**Published online:** December 6, 2019

**Abstract**

***BACKGROUND***

Non-steroid anti-inflammatory drugs (NSAIDs) have played a crucial role in the treatment of osteoarthritis, especially in the early stages. However, the cardiovascular risk and adverse gastrointestinal reactions of oral NSAIDs in elderly people cannot be underestimated. Intra-articular injection of NSAIDs may be a new attempt for early knee osteoarthritis treatment. Parecoxib may be a suitable drug for intra-articular injection.

***AIM***

To observe the clinical efficacy of the intra-articular injection of parecoxib for early knee osteoarthritis.

***METHODS***

Early knee osteoarthritis patients (*n* = 110) were retrospectively analyzed. These patients were divided into three groups: Basic treatment + oral glucosamine (group A, *n* = 37), oral celecoxib + basic treatment + oral glucosamine (group B, *n* = 37), and intra-articular injection of parecoxib + basic treatment + oral glucosamine (group C, *n* = 36). Intra-articular injection of parecoxib was performed once every 2 wk at a dose of 40 mg each time, for three times total. The three groups were compared in terms of visual analogue scale (VAS) scores, Hospital for Special Surgery (HSS) scores and patient satisfaction before and after treatment. The levels of inflammatory cytokines in the synovial fluid were detected in the three groups before and after treatment.

***RESULTS***

All patients were followed up for an average of 15.5 ± 2.7 mo. The clinical efficacy was estimated by VAS and HSS scores at 12 mo after treatment. Inflammatory cytokine levels in the synovial fluid were evaluated at 3 mo after treatment. VAS and HSS scores were significantly improved in each group compared with before (*P* < 0.001). There were significant differences among the three groups in VAS and HSS scores (*P* < 0.001). The clinical efficacy of group C was superior to that of groups A and B (*P* < 0.001), while group B outperformed group A in this respect (*P* < 0.001). The patient satisfaction was the highest in group C (*P* < 0.001). After treatment, the levels of tumor necrosis factor α (TNF-α) and interleukin (IL)-6 in the synovial fluid decreased in each group compared with before (*P* < 0.001), while the levels of IL-10 increased (*P* < 0.001). The three groups differed significantly in the levels of TNF-a, IL-6 and IL-10 in the synovial fluid after treatment (*P* < 0.001).

***CONCLUSION***

For patients with early knee osteoarthritis, intra-articular injection of parecoxib could effectively improve clinical symptoms. This method may be a reliable alternative for early knee osteoarthritis.

**Key words:** Knee osteoarthritis; Intra-articular injection; Parecoxib; Non-steroid anti-inflammatory drugs

**© The Author(s) 2019.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** Among patients with early knee osteoarthritis, intra-articular injection of parecoxib can significantly improve clinical symptoms and avoid the adverse events associated with long-term oral use of non-steroid anti-inflammatory drugs. This treatment can be a suitable treatment alternative.

**Citation:** Lu L, Xie Y, Gan K, Huang XW. Comparison of intra-articular injection of parecoxib *vs* oral administration of celecoxib for the clinical efficacy in the treatment of early knee osteoarthritis. *World J Clin Cases* 2019; 7(23): 3971-3979

URL: <https://www.wjgnet.com/2307-8960/full/v7/i23/3971.htm>

DOI: https://dx.doi.org/10.12998/wjcc.v7.i23.3971

**INTRODUCTION**

Osteoarthritis (OA) is a degenerative joint disease commonly found in elderly people[1-5]. Early clinical symptoms of OA include joint pain and restricted mobility, and it may also cause joint deformities in later stages. The incidence of OA has been rising every year, which not only affects patient quality-of-life, but also causes considerable economic and mental burdens. The major treatments for OA include changing unhealthy lifestyles and modes of movement in the early stages, strengthening functional training of periarticular muscles and joints, physical therapy, and oral or external application of non-steroid anti-inflammatory drugs (NSAIDs) to relieve the symptoms[1-5]. However, patients usually require joint replacement in late stages. In spite of the extensive clinical use of selective COX-2 inhibitors (*e.g*., celecoxib and etoricoxib), the incidence of adverse gastrointestinal reactions remains high[6,7]. Moreover, the cardiovascular risk of oral NSAIDs can never be underestimated, and the compliance with the long-term use of NSAIDs remains low[8]. The analgesic effect of topical agents is poor, and adverse skin events may occur from time to time[1,2,4,5]. Intra-articular medication is a treatment strategy worthy of wider clinical popularization. Parecoxib is a novel type of NSAID and can be injected intravenously. This agent can selectively inhibit the COX-2 pathway. Based on the pharmacokinetics of parecoxib, the plasma half-life of parecoxib is only 22 min because of its rapid conversion to valdecoxib. This blocks the synthesis of prostaglandins in peripheral and central regions, increases the pain threshold, inhibits hypersensitivity of the pain threshold, and produces anti-inflammatory and analgesic effects. Parecoxib is conventionally used for postoperative analgesia in anesthesiology and surgery departments[9,10]. Intra-articular injection of parecoxib can block the inflammatory cascade in early OA by the same mechanism. However，it is undeniable that intra-articular injection has a series of possible adverse events, such as injection site inflammation, intra-articular hemorrhage, meniscus or cartilage damage, and even septic arthritis. Thus, this method is rarely discussed in the literature both at home and abroad[11]. In this study, 36 cases with early knee OA (KOA) who received intra-articular injections of parecoxib from September 2016 to October 2017 were analyzed retrospectively, and the clinical efficacy was compared with those receiving other treatments.

**MATERIALS AND METHODS**

***Subjects***

From September 2016 to October 2017, 110 patients with early KOA (51 males and 59 females, aged 45- to 64-years-old, with an average age of 52.0 ± 4.1 years) who received treatment at the outpatient clinic of the orthopedics and rheumatology departments and had intact follow-up data were retrospectively reviewed according to the inclusion and exclusion criteria. Inclusion criteria: (1) Diagnosed as KOA according to the American Academy of Orthopedic Surgeons (AAOS) Guidelines for the Diagnosis and Treatment of Knee Osteoarthritis; (2) Receiving initial treatment with a medical history shorter than 6 mo; excluding those with moderate amounts of effusion in the joint upon musculoskeletal ultrasound); (3) Clinical staging: Kellgren-Lawrence (K-L) grade 0-II upon plain X-ray scan; (4) Age > 54 years old; (5) No history of severe knee joint trauma or ligament rupture, with intact bone and ligament structures; (6) Knee joint having at least 100° mobility, with varus and valgus deformity < 5°; and (7) Consenting to intra-articular puncture[1]. Exclusion criteria: (1) Inflammatory lesions of the knee joint, such as rheumatoid arthritis, reactive arthritis, gout and ankylosing spondylitis; (2) Infectious arthritis; (3) Severe osteoporosis; (4) History of knee joint surgery; (5) Allergic to sulfonamides; (6) Severe neuropsychiatric disorders or organic diseases of the heart, liver and kidneys; and (7) Poor compliance and uncooperative with the follow-up. All patients provided informed consent and agreed to participate in the study. This study was approved by the ethics committee of our hospital. The ethical committee approval number is 2016NL-036-02.

According to the treatment modalities, these patients were divided into three groups: basic treatment + oral glucosamine (group A, *n* = 37), oral celecoxib + basic treatment + oral glucosamine (group B, *n* = 37), and intra-articular injection of parecoxib + basic treatment + oral glucosamine (group C, *n* = 36). All patients were asked in detail about their medical history, and received X-ray scans and musculoskeletal ultrasounds. All of them signed the informed consent for intra-articular puncture. There were no significant differences between the three groups in terms of demographic information (gender, age, K-L grade, course of disease, body mass index) (Table 1).

***Treatment modalities***

All 37 patients in group A received basic treatment, which consisted of the following: health education, recommendations for changes to an unhealthy lifestyle and modes of movement, instructing the patients on the necessity of avoiding long-time running, jumping, and squatting, avoiding stair and mountain climbing as much as possible, and reducing weight. On this basis, they were given oral glucosamine sulfate (viatril-S, Rottapharm Ltd., CFDA approval No. H20090797) tid, at a dose of 0.5 each time before meals. The duration of medication was 12 consecutive wk.

Patients in group B received basic treatment, as in group A. On this basis, they took celecoxib orally (Celebrex, Pfizer Pharmaceuticals Limited, CDFA approval No. J20140072) bid, at a dose of 0.2 g each time, for 12 consecutive wk. Moreover, they were also given oral glucosamine sulfate using the same dose as group A.

Patients in group C received basic treatment, as in group A. After the informed consent and risk disclosure statement were signed, patients in group C received intra-articular injection of 40 mg parecoxib (Pfizer Pharmaceuticals Limited, CDFA approval No. J20130044). Before the injection, 40 mg parecoxib was dissolved in 3 mL of normal saline. The patients took a supine position with the affected lower limb straightened out naturally. The skin was disinfected with iodophor. After laying the sterile drape, the needle was inserted from the lateral side of the patella, with the needle tip inclining towards the middle. A small amount of synovial fluid was extracted after the intra-articular puncture was successful. Later, an intra-articular injection of 40 mg parecoxib was performed. At the end of the injection, the knee joint moved properly so that the injected liquid could be evenly distributed. Intra-articular injection of parecoxib was performed once every 2 wk, at a dose of 40 mg each time, for three times total. Moreover, they were also given oral glucosamine sulfate using the same dose as group A. Synovial fluid was extracted *via* intra-articular puncture for all patients before treatment and at 3 mo after treatment.

***Observation indicators and methods***

**Visual analogue scale scores:** Visual analogue scale (VAS) scores before treatment and at 12 mo after treatment were recorded for the three groups. This involved two senior physicians evaluating VAS scores as the patients climbed up and down stairs or were squatting.

**Hospital for Special Surgery scores:** Hospital for Special Surgery (HSS) scores before treatment and at 12 mo after treatment were recorded for the three groups (HSS Knee Score)[12]. Knee joint function was separately evaluated by two senior physicians.

**Determination of inflammatory cytokine levels in the synovial fluid:** Before treatment and at 3 mo after treatment, synovial fluid was extracted for the three groups to determine the levels of inflammatory cytokines, including tumor necrosis factor α (TNF-α), interleukin (IL)-6 and IL-10. Detections were conducted by using an ELISA kit (R and D Systems, United States) in accordance with the manufacturer’s instruction.

**Patient satisfaction:** Patient satisfaction was recorded after administering the different treatments for 12 mo.

**Efficacy evaluation criteria:** Clinical efficacy was evaluated based on HSS scores of the knee joint from the following dimensions: Pain (30 points), function (22 points), mobility (18 points), muscle tone (10 points), flexion deformity (10 points) and stability (10 points). The total score was 100 points, and the score = 85 points was defined as excellent, 70-84 scores as good, 60-69 points as fair, and < 60 points as poor.

***Statistical analysis***

Statistical analyses were performed using STATA 15.0 software. Continuous numerical variables obeying normal distributions in the three groups were further analyzed by ANOVA, and an intergroup comparison was conducted using a Scheff test. Paired *t*-tests were performed within each group before and after treatment. Categorical variables were analyzed by the chi-square test or Fisher’s exact test, with the significance level set at 0.05.

**RESULTS**

All patients were followed up for an average of 15.5 ± 2.7 mo, and none of the patients were lost during the follow-up. VAS scores of all patients decreased after treatment (Table 2), while HSS scores increased (Table 3). The levels of inflammatory cytokines TNF-α and IL-6 in the synovial fluid (Table 4) decreased, while the levels of IL-10 increased (Table 4). All of these changes were significant (*P* < 0.001), indicating that all treatments were effective against early KOA to a certain extent. After treatment, there were significant differences in VAS scores, HSS scores and levels of the inflammatory cytokines TNF-α, IL-6 and IL-10 in the synovial fluid among the three groups (*P* < 0.001). The results of group C were significantly different from those of groups A and B (*P* < 0.001), and the results of group B were significantly different from those of group A (*P* < 0.001). As to patient satisfaction, there were significant differences among the three groups (*P* < 0.001), with the highest satisfaction found in group C.

**DISCUSSION**

OA is a degenerative joint disease that typically affects elderly people. This medical condition can greatly impair patient quality-of-life, and also cause significant economic and mental burdens for patient families. OA treatment should follow the principles of early diagnosis and early treatment, which is crucial for relieving symptoms, reducing complications, lowering disability rates, and lessening both family and social burdens.

The current guidelines for the diagnosis and treatment of OA provide detailed introduction for the ladder-like OA treatment strategy, which consists of basic treatment, medication therapy, surgery and traditional Chinese medicine[1,2,4,5]. Medication therapy predominantly uses NSAIDs, either orally or topically. Topical NSAIDs take effect slowly, and may incur complications such as adverse skin events. Therefore, oral NSAIDs remain the mainstream treatment for early OA. Most OA patients are elderly people, who typically suffer from several diseases, particularly gastrointestinal, heart, liver and kidney diseases. Therefore, the selection of the type and dosage of medicine should be very carefully determined. Before the medication therapy begins, risk factors should first be evaluated, and medication safety should be prioritized to reduce adverse events. NSAIDs should be prescribed with caution for patients with a high cardiovascular risk, including selective COX-2 inhibitors (*e.g*., celecoxib)[8]. In clinical practice, patients with heart and gastrointestinal diseases cannot take NSAIDs orally, and therefore suffer from poor treatment efficacy. In addition, the long-term use of oral NSAIDs, even selective COX-2 inhibitors, may cause damage to the gastrointestinal tract. Patients usually show poor compliance with oral medications. Besides, the long-term use of oral drugs can be costly, which further leads to relapse or aggravation of the diseases. Patients are usually unsatisfied with treatment outcomes, and urgently need new solutions for the above problems.

Intra-articular injection of drugs is a more direct treatment, which promotes the enrichment of drugs at the target site, thereby relieving pain and improving joint function more effectively[3,13-15]. However, as an invasive method, intra-articular injection may increase the risk of joint infection. The commonly used drugs for intra-articular injection include glucocorticoids, sodium hyaluronate, chitosan and platelet-rich plasma. Hormone therapy has a potent anti-inflammatory effect, but may cause irreversible damage to the articular cartilage and hence have a poor long-term outcome. AAOS Guidelines for the Diagnosis and Treatment of Osteoarthritis does not recommend the intra-articular injection of sodium hyaluronate[1]. In the 2008 version of the Guidelines, it is indicated that the efficacy of the treatment is uncertain[16]. In the 2009 version of the Osteoarthritis Research Society International guidelines for OA, the intra-articular injection of sodium hyaluronate became “level 2” treatment for KOA, but was not recommended for individuals with polyarticular OA”[5]. In the 2008 version of the guidelines for viscosupplementation for KOA, only cross-linked HA is allowed for single injections[3]. Hence, the intra-articular injection of sodium hyaluronate is still controversial and largely used as a second-line treatment. Chitosan and platelet-rich plasma are less costly, and their efficacy is under further investigation. Guidelines do not mention the use of chitosan or platelet-rich plasma, or only claim that their efficacy remains uncertain[1,2,4,5]. There is a long way to go before the above drugs will be used in the clinic. Drugs with a definite anti-inflammatory effect, no apparent side-effects and low cost are needed for intra-articular injections. In this study, a novel type of selective COX-2 inhibitor, parecoxib, was chosen for intra-articular injection.

Parecoxib was once used in intravenous and intramuscular injections with high safety and reliability. Few reports are available as to its use in intra-articular injection[11]. After local injection, parecoxib can be hydrolyzed into valdecoxib, which can further block the local synthesis of prostaglandin from arachidonic acid, thus achieving an anti-inflammatory and analgesic effect. Parecoxib’s inhibitory effect on COX-2 is 28,000 times stronger than its effect on COX-1, and it can achieve a potent anti-inflammatory and analgesic effect. As far as the pathogenesis of OA is concerned, inflammatory cytokines are involved in the regulation of the entire process. Inflammation and pain stimuli will cause the secretion of TNF-α by many cells. After binding to its receptors, TNF-α can rapidly trigger the NF-κB signaling pathway. As a result, proinflammatory cytokines such as IL-1, IL-6 and IL-8 will be secreted through a series of signal transduction steps. This further leads to inflammatory cascades and the activation of the inflammatory network, which significantly inhibits the production and release of anti-inflammatory cytokines such as IL-4, IL-10 and IL-13. IL-6 is the primary proinflammatory cytokine in inflammatory responses of the acute stage. It is directly related to OA inflammatory symptoms, such as pain and synovial edema[17,18]. It has been reported that parecoxib not only inhibits the synthesis of prostaglandin, but also has potent anti-inflammatory and analgesic effects[19]. Moreover, parecoxib can alleviate inflammatory responses by inhibiting activation of the NF-κB signaling pathway, and hence inhibit IL-6 transcription. Previous studies have shown that prostaglandin inhibits IL-10 synthesis, while parecoxib promotes IL-10 release and relieves the inflammatory response by inhibiting prostaglandin synthesis[19]. The above studies on the anti-inflammatory mechanism agree with our measurements of inflammatory cytokine levels before and after treatment. These results explain the good clinical efficacy of the intra-articular injection of parecoxib for early KOA from the perspective of basic research.

In this study, we evaluated VAS scores and HSS scores before and after treatment, as well as the degree of patient satisfaction. It was preliminarily proven that the intra-articular injection of parecoxib outperformed oral celecoxib in the treatment of early KOA. After intra-articular injection, a large amount of liquid drugs rapidly accumulates in the articular cavity. Therefore, the local concentration of the drug at the target site is high. However, there are few blood vessels in the articular cavity of the knee, and drug absorption and metabolism *via* blood circulation are slow. For this reason, the anti-inflammatory and analgesic effects are more enduring. Local medication has very little systemic impact, and so this treatment also applies to elderly OA patients with cerebrovascular, cardiovascular and gastrointestinal diseases. Moreover, there is no need for long-term oral use, which greatly improves the compliance and reduces the economic burden for patients. Due to these benefits, we recommend the clinical use of intra-articular injection of parecoxib.

Our study has certain limitations. First, limited by the nature of the retrospective study design, it must be emphasized that patient selection and evaluation biases are inevitable. Second, our sample size remains small and the duration of follow-up was short. In future research, we should use strict prospective randomized clinical trials to verify the findings of our results through longer follow-ups. It should be noted that intra-articular injection is an invasive procedure, which carries a certain risk of joint infection, especially for elderly patients with such underlying diseases as diabetes. Given the limited number of literature reports in this respect at home and abroad, more research should be conducted on the dosage and frequency of parecoxib administration by intra-articular injection. In addition, it remains unclear whether local high-concentration NSAIDs will induce other joint complications, and also whether combined administration is feasible with sodium hyaluronate.

Taken together, among patients with early KOA, intra-articular injection of parecoxib can significantly improve clinical symptoms and prevent adverse events associated with the long-term oral use of NSAIDs. This treatment can be a suitable treatment alternative.

**Article Highlights**

***Research background***

Oral non-steroid anti-inflammatory drugs (NSAIDs) are often used for the treatment of osteoarthritis. However, in elderly people, oral NSAIDs have certain side-effects especially in the incidence of adverse gastrointestinal reactions and cardiovascular risk. Meanwhile, the compliance with long-term use of NSAIDs is low in early osteoarthritis.

***Research motivation***

A new solution is needed for patients with early osteoarthritis, especially for those who cannot take NSAIDS orally. Intra-articular injection of drugs is a direct and effective treatment. It is a challenge to find suitable NSAIDs for intra-articular injection. Parecoxib is conventionally used for postoperative analgesia by an intravenous route of administration in the surgery department. The feasibility and effectiveness of the intra-articular injection of parecoxib should be explored.

***Research objectives***

A retrospective study was performed to observe and investigate the clinical efficacy of the intra-articular injection of Parecoxib to treat patients with early knee osteoarthritis (KOA).

***Research methods***

Three groups of patients (110 cases in total) underwent interventions of three separate treatment methods. By comparing visual analogue scale (VAS), Hospital for Special Surgery (HSS) scores and levels of different inflammatory cytokines in synovial fluid before and after treatment, the clinical efficacy of intra-articular injections of Parecoxib were evaluated.

***Research results***

The clinical efficacy of the intra-articular injection group in the treatment of early KOA was confirmed to be superior to the others, whether it be in terms of VAS and HSS scores or the variation of different inflammatory cytokine levels.

***Research conclusions***

Compared with oral NSAIDS, intra-articular injection of Parecoxib has better clinical efficacy in the treatment of early KOA. This method can avoid the side-effects associated with the long-term oral use of NSAIDs, and should be an option for clinical application.

***Research perspectives***

Osteoarthritis treatment methods require continual improvement and optimization. More randomized clinical trial studies are always necessary to improve and verify our findings.

**REFERENCES**

1 **Brown GA**. AAOS clinical practice guideline: treatment of osteoarthritis of the knee: evidence-based guideline, 2nd edition. *J Am Acad Orthop Surg* 2013; **21**: 577-579 [PMID: 23996989 DOI: 10.5435/JAAOS-21-09-577]

2 **Hochberg MC**, Altman RD, April KT, Benkhalti M, Guyatt G, McGowan J, Towheed T, Welch V, Wells G, Tugwell P; American College of Rheumatology. American College of Rheumatology 2012 recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee. *Arthritis Care Res (Hoboken)* 2012; **64**: 465-474 [PMID: 22563589 DOI: 10.1002/acr.21596]

3 **Raman R**, Henrotin Y, Chevalier X, Migliore A, Jerosch J, Montfort J, Bard H, Baron D, Richette P, Conrozier T. Decision Algorithms for the Retreatment with Viscosupplementation in Patients Suffering from Knee Osteoarthritis: Recommendations from the EUROpean VIScosupplementation COnsensus Group (EUROVISCO). *Cartilage* 2018; **9**: 263-275 [PMID: 29110511 DOI: 10.1177/1947603517693043]

4 **Zhang W**, Doherty M, Peat G, Bierma-Zeinstra MA, Arden NK, Bresnihan B, Herrero-Beaumont G, Kirschner S, Leeb BF, Lohmander LS, Mazières B, Pavelka K, Punzi L, So AK, Tuncer T, Watt I, Bijlsma JW. EULAR evidence-based recommendations for the diagnosis of knee osteoarthritis. *Ann Rheum Dis* 2010; **69**: 483-489 [PMID: 19762361 DOI: 10.1136/ard.2009.113100]

5 **Bannuru RR**, Osani MC, Vaysbrot EE, Arden NK, Bennell K, Bierma-Zeinstra SMA, Kraus VB, Lohmander LS, Abbott JH, Bhandari M, Blanco FJ, Espinosa R, Haugen IK, Lin J, Mandl LA, Moilanen E, Nakamura N, Snyder-Mackler L, Trojian T, Underwood M, McAlindon TE. OARSI guidelines for the non-surgical management of knee, hip, and polyarticular osteoarthritis. *Osteoarthritis Cartilage* 2019; **27**: 1578-1589 [PMID: 31278997 DOI: 10.1016/j.joca.2019.06.011]

6 **Chan FKL**, Ching JYL, Tse YK, Lam K, Wong GLH, Ng SC, Lee V, Au KWL, Cheong PK, Suen BY, Chan H, Kee KM, Lo A, Wong VWS, Wu JCY, Kyaw MH. Gastrointestinal safety of celecoxib versus naproxen in patients with cardiothrombotic diseases and arthritis after upper gastrointestinal bleeding (CONCERN): an industry-independent, double-blind, double-dummy, randomised trial. *Lancet* 2017; **389**: 2375-2382 [PMID: 28410791 DOI: 10.1016/S0140-6736(17)30981-9]

7 **Feng X**, Tian M, Zhang W, Mei H. Gastrointestinal safety of etoricoxib in osteoarthritis and rheumatoid arthritis: A meta-analysis. *PLoS One* 2018; **13**: e0190798 [PMID: 29320568 DOI: 10.1371/journal.pone.0190798]

8 **Nissen SE**, Yeomans ND, Solomon DH, Lüscher TF, Libby P, Husni ME, Graham DY, Borer JS, Wisniewski LM, Wolski KE, Wang Q, Menon V, Ruschitzka F, Gaffney M, Beckerman B, Berger MF, Bao W, Lincoff AM; PRECISION Trial Investigators. Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis. *N Engl J Med* 2016; **375**: 2519-2529 [PMID: 27959716 DOI: 10.1056/NEJMoa1611593]

9 **Essex MN**, Choi HY, Bhadra Brown P, Cheung R. A randomized study of the efficacy and safety of parecoxib for the treatment of pain following total knee arthroplasty in Korean patients. *J Pain Res* 2018; **11**: 427-433 [PMID: 29503579 DOI: 10.2147/JPR.S147481]

10 **Bian YY**, Wang LC, Qian WW, Lin J, Jin J, Peng HM, Weng XS. Role of Parecoxib Sodium in the Multimodal Analgesia after Total Knee Arthroplasty: A Randomized Double-blinded Controlled Trial. *Orthop Surg* 2018; **10**: 321-327 [PMID: 30485685 DOI: 10.1111/os.12410]

11 **Jean YH**, Wen ZH, Chang YC, Hsieh SP, Tang CC, Wang YH, Wong CS. Intra-articular injection of the cyclooxygenase-2 inhibitor parecoxib attenuates osteoarthritis progression in anterior cruciate ligament-transected knee in rats: role of excitatory amino acids. *Osteoarthritis Cartilage* 2007; **15**: 638-645 [PMID: 17198754 DOI: 10.1016/j.joca.2006.11.008]

12 **Insall JN**, Ranawat CS, Aglietti P, Shine J. A comparison of four models of total knee-replacement prostheses. *J Bone Joint Surg Am* 1976; **58**: 754-765 [PMID: 956219 DOI: 10.2106/00004623-197658060-00003]

13 **Henrotin Y**, Chevalier X, Raman R, Richette P, Montfort J, Jerosch J, Baron D, Bard H, Carrillon Y, Migliore A, Conrozier T. EUROVISCO Guidelines for the Design and Conduct of Clinical Trials Assessing the Disease-Modifying Effect of Knee Viscosupplementation. *Cartilage* 2018; 1947603518783521 [PMID: 29972025 DOI: 10.1177/1947603518783521]

14 **Conrozier T**, Monfort J, Chevalier X, Raman R, Richette P, Diraçoglù D, Bard H, Baron D, Jerosch J, Migliore A, Henrotin Y. EUROVISCO Recommendations for Optimizing the Clinical Results of Viscosupplementation in Osteoarthritis. *Cartilage* 2018; 1947603518783455 [PMID: 29926748 DOI: 10.1177/1947603518783455]

15 **Hunter DJ**. Viscosupplementation for osteoarthritis of the knee. *N Engl J Med* 2015; **372**: 1040-1047 [PMID: 25760356 DOI: 10.1056/NEJMct1215534]

16 **Zhang W**, Moskowitz RW, Nuki G, Abramson S, Altman RD, Arden N, Bierma-Zeinstra S, Brandt KD, Croft P, Doherty M, Dougados M, Hochberg M, Hunter DJ, Kwoh K, Lohmander LS, Tugwell P. OARSI recommendations for the management of hip and knee osteoarthritis, Part II: OARSI evidence-based, expert consensus guidelines. *Osteoarthritis Cartilage* 2008; **16**: 137-162 [PMID: 18279766 DOI: 10.1016/j.joca.2007.12.013]

17 **Mabey T**, Honsawek S. Cytokines as biochemical markers for knee osteoarthritis. *World J Orthop* 2015; **6**: 95-105 [PMID: 25621214 DOI: 10.5312/wjo.v6.i1.95]

18 **Panina SB**, Krolevets IV, Milyutina NP, Sagakyants AB, Kornienko IV, Ananyan AA, Zabrodin MA, Plotnikov AA, Vnukov VV. Circulating levels of proinflammatory mediators as potential biomarkers of post-traumatic knee osteoarthritis development. *J Orthop Traumatol* 2017; **18**: 349-357 [PMID: 29058227 DOI: 10.1007/s10195-017-0473-8]

19 **Zhu Y**, Wang S, Wu H, Wu Y. Effect of perioperative parecoxib on postoperative pain and local inflammation factors PGE2 and IL-6 for total knee arthroplasty: a randomized, double-blind, placebo-controlled study. *Eur J Orthop Surg Traumatol* 2014; **24**: 395-401 [PMID: 23483320 DOI: 10.1007/s00590-013-1203-4]

**P-Reviewer:** Tangtrakulwanich B **S-Editor:** Yan JP

**L-Editor:** Filipodia **E-Editor:** Qi LL

**Specialty type:** Medicine, research and experimental  
**Country of origin:** China   
**Peer-review report classification**  
**Grade A (Excellent):** 0  
**Grade B (Very good):** 0  
**Grade C (Good):** C  
**Grade D (Fair):** 0 **Grade E (Poor):** 0

**Table 1 Comparison of the baseline information of three groups**

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Group** | **Case** | **Gender** | | **Age in yr,**  **mean ± SD** | **Kellgren-Lawrence grade** | | | **Course of disease (mo)** | **BMI (kg/m2)** | **Occupation** |  | **Marital status** |  | **Education Level** |  |  | **Underlying disease** |
|  |  | **Male** | **Female** | **Grade 0** | **Grade I** | **Grade II** |  |  | **Manual worker** | [**Mental worker**](http://www.baidu.com/link?url=7hTSL-POd2_93v6zcry3uMlijZX0CSVbBQ8LaEUe_z9QE6AeDhVZpnJ5K33t_GG0v91_NI8pA4YTGjO8WfGuQ_CyjNzrp7NLvd5GPTg_l2rAJuomq3_DyxLRNxkjniyf) | **Married** | **Single** | **Primary** | **Secondary** | **Higher** | **HT/DM/CHD** |
| Group A | 37 | 17 | 20 | 52.1 ± 4.7 | 5 | 21 | 11 | 4.7 ± 1.0 | 24.8 ± 1.2 | 26 | 11 | 35 | 2 | 5 | 25 | 7 | 10/3/2 |
| Group B | 37 | 19 | 18 | 51.7 ± 3.5 | 8 | 19 | 10 | 4.8 ± 0.9 | 25.0 ± 1.3 | 27 | 10 | 36 | 1 | 4 | 24 | 9 | 11/4/3 |
| Group C | 36 | 15 | 21 | 52.1 ± 4.2 | 6 | 19 | 11 | 4.9 ± 1.0 | 24.9 ± 1.0 | 25 | 11 | 35 | 1 | 4 | 24 | 8 | 9/1/1 |
| *F*/χ2 value |  | 0.692 | | 0.150 | 0.91 | | | 0.17 | 0.23 | 0.121 | | 0.498 | | 0.41 | | | 1.415 |
| *P* value |  | 0.707 | | 0.86 | 0.923 | | | 0.847 | 0.796 | 0.941 | | 0.779 | | 0.982 | | | 0.842 |

BMI: Body mass index; HT: Hypertension; DM: Diabetes mellitus; CHD: Coronary heart disease.

**Table 2 Comparison of visual analogue scale scores and satisfaction of patients in the three groups before and after treatment**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Group** | **Case** | **VAS scores** | | **Patients’ satisfaction degree: satisfied/unsatisfied** |
| **Before** | **After** |
| Group A | 37 | 4.1 ± 0.7 | 3.4 ± 0.6 | 8/29 |
| Group B | 37 | 4.0 ± 0.6 | 1.8 ± 0.6 | 33/4 |
| Group C | 36 | 4.1 ± 0.7 | 0.8 ± 0.5 | 35/1 |
| *F/*χ2 value |  | 0.09 | 179.97 | 59.38 |
| *P* value |  | 0.9102 | < 0.001 | < 0.001 |

Data are presented as mean ± SD. VAS: Visual analogue scale.

**Table 3 Comparison of Hospital for Special Surgery Knee scores in the three groups before and after treatment**

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Group** | **Case** | **HSS scores before treatment** | | | | | | | **HSS scores before treatment** | | | | | | | |
|  |  | **Pain** | **Function** | **Mobility** | **Muscle tone** | **Flexion deformity** | **Stability** | **Total score** | | **Pain** | **Function** | **Mobility** | **Muscle tone** | **Flexion deformity** | **Stability** | **Total scores** | |
| Group A | 37 | 16.7 ± 2.4 | 20.2 ± 0.6 | 14.5 ± 1.0 | 10 | 8.4 ± 0.8 | 9.7 ± 0.7 | 79.5 ± 2.8 | | 19.0 ± 2.0 | 20.6 ± 0.9 | 14.8 ± 0.9 | 10 | 8.4 ± 0.8 | 9.7 ± 0.7 | 82.5 ± 2.5 | |
| Group B | 37 | 16.9 ± 2.5 | 20.1 ± 0.5 | 14.5 ±1.2 | 10 | 8.6 ± 0.9 | 9.8 ± 0.6 | 79.9 ± 3.2 | | 22.3 ± 4.0 | 21.3 ± 1.0 | 14.9 ± 1.1 | 10 | 8.6 ± 0.9 | 9.8 ± 0.6 | 86.9 ± 4.7 | |
| Group C | 36 | 17.2 ± 2.5 | 20.2 ± 0.6 | 14.3 ± 1.0 | 10 | 8.4 ± 0.8 | 9.7 ± 0.8 | 79.7 ± 3.3 | | 27.8 ± 2.5 | 21.5 ± 0.9 | 15.2 ± 1.0 | 10 | 8.4 ± 0.8 | 9.7 ± 0.8 | 92.5 ± 3.3 | |
| *F* value |  | 0.34 | 0.39 | 0.8 | - | 0.77 | 0.31 | 0.14 | | 80.27 | 9.67 | 1.12 | - | 0.77 | 0.31 | 69.17 | |
| *P* value |  | 0.710 | 0.680 | 0.452 | 1 | 0.466 | 0.736 | 0.87 | | < 0.001 | < 0.001a | 0.329 | 1 | 0.466 | 0.736 | < 0.001 | |

aIntergroup comparison of single item (Function item) of Hospital for Special Surgery after treatment: there were significant differences in group B and C compared with group A; there were no significant differences between group B and C. Data are presented as mean ± SD. HSS: Hospital for Special Surgery.

**Table 4 Comparison of inflammatory cytokine levels in the synovial fluid in the three groups before and after treatment**

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Group** | **Case** | **IL-6 (pg/mL)** | | | **TNF-α (pg/mL)** | | | **IL-10 (pg/mL)** | |
|  |  | **Before** | **After** | **Before** | | **After** | **Before** | | **After** |
| Group A | 37 | 418.7 ± 27.8 | 384.1 ± 25.0b | 3.66 ± 0.38 | | 3.03 ± 0.28b | 5.47 ± 0.32 | | 6.04 ± 0.49b |
| Group B | 37 | 415.7 ± 28.2 | 212.6 ± 23.4b | 3.53 ± 0.47 | | 2.07 ± 0.33b | 5.52 ± 0.30 | | 7.46 ± 0.44b |
| Group C | 36 | 412.7 ± 37.1 | 137.8 ± 29.0b | 3.56 ± 0.53 | | 1.45 ± 0.26b | 5.42 ± 0.43 | | 8.72 ± 0.60b |
| *F* value |  | 0.34 | 871.17 | 0.70 | | 275.41 | 0.87 | | 246.74 |
| *P* value |  | 0.715 | < 0.001 | 0.497 | | < 0.001 | 0.422 | | < 0.001 |

bComparison of interleukin-6, Tumor necrosis factor-α and interleukin-10 levels for each group before and after treatment, significant differences were found (*P* < 0.001). Data are presented as mean ± SD of pg/mL. IL-6: Interleukin-6; TNF-α: Tumor necrosis factor-α; IL-10: Interleukin-10.